Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)
- 15 November 1996
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 28 (6) , 1437-1443
- https://doi.org/10.1016/s0735-1097(96)00343-9
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosisThe Lancet, 1993
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Direct intraarterial wall injection of microparticles via a catheter: A potential drug delivery strategy following angioplastyAmerican Heart Journal, 1991
- Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplastyAmerican Heart Journal, 1989
- Angiographic morphology of restenosis after percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1987
- Effect of heparin on vascular smooth muscle cells. I. Cell metabolismJournal of Cellular Physiology, 1985
- Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood instituteThe American Journal of Cardiology, 1984
- Nonoperative Dilatation of Coronary-Artery StenosisNew England Journal of Medicine, 1979
- Suppression by heparin of smooth muscle cell proliferation in injured arteriesNature, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958